Isotechnika Pharma Inc.'s NICAM Compounds Demonstrate Positive Anti-Hepatitis C Virus Activity in Secondary Level Testing at National Institutes of Health (NIH)-Funded Labs

Published: Dec 07, 2012

EDMONTON, Alberta, Dec. 6, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") is pleased to announce positive anti-hepatitis C virus ("HCV") results from the second round of in vitro testing of its cyclophilin antagonist molecules ("NICAMs"). Contractors funded by the National Institute of Allergy and Infectious Diseases ("NIAID"), part of the U.S. National Institutes of Health ("NIH"), carried out the testing.

Back to news